ChromoCure, Inc. Files Consolidated Financial Statements With OTC Disclosure Service

RENO, NV--(Marketwire - September 02, 2009) -

ChromoCure, Inc. (PINKSHEETS: KKUR) announced it filed its consolidated GAAP financial statements for the year 2007 through 2009. These financials are published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines.

As promised to investors, completing the requirements to achieve “current information” status is part of the company’s 2009 business plan. The Company believes it has met these requirements. Upon review by the OTC Disclosure staff, the Company anticipates being issued “Current Information” status. Investors can access the Company’s public filings at www.pinksheets.com under the Company’s “Filings” tab.

The Company continues to execute its business plan and stockholders should expect regularly and timely updates on the company’s progress. Ongoing financial reporting and related disclosures will be timely published as part of the Company’s ongoing disclosure practices.

Updates will be timely published on the following:

-- Announcement of joint research and development agreement -- Initial scanner installations with diagnostic labs -- Elimination of significant long-term liabilities and removal from the Balance Sheet -- Acquisition of intellectual property, technology, and subsequent patent filings assets -- Additional appointments to the Company’s Advisory Boards -- Acquisition of profitable labs to expand the Company’s operations -- Regular updates and commentary on the Company’s technology. 

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company’s systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.

The Company’s technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.